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Influence of Treatment Modalities on Body Weight in Acute 
Lymphoblastic Leukemia 
J.J. Croot-Loonen, MD, B.J. Otten, MD, PhD, 
M.A. van’t Hof, PhD, R.J.J. Lippens, MD, PhD, and C.B.A. Stoelinga, MD, PhD 
Weight for height of 92 patients (51 girls and 
41 boys) treated for acute lymphoblastic leuke- 
mia (ALL) was evaluated in a longitudinal study. 
Fifty-four patients received cranial irradiation 
(CI) with a dose of 18 or 24 Gy and 38 patients 
did not receive CI. Seventy-seven patients were 
treated according to a normal-risk protocol and 
15 patients received more intensive chemother- 
apy according to a high-risk protocol. In most 
of the patients the duration of follow-up was 12 
years for irradiated patients and 4.5 years for 
the nonirradiated patients. 
Thirty of 92 patients were treated according 
to a protocol without CI, but with a difference 
in the useof corticosteroids: 19 patients received 
dexamethasone during the remission-induction 
and maintenance treatment and 11 patients re- 
ceived prednisone. The influence of dexametha- 
sone vs. prednisone, sex, CI and high-dose 
vs.low-dose Chemotherapy on weight for height 
was evaluated. Patients who received dexameth- 
asone showed a significant increase in weight 
for height immediately after the start of therapy. 
In patients who received CI, weight for height 
significantly increased after the first year of treat- 
ment. The overweight in these patients persisted 
during the whole follow-up period. The weight 
for height of patients treated with prednisone 
and of patients who did not receive CI was below 
the mean of the normal population during treat- 
ment but was not different from normal after 
cessation of therapy. No difference in weight 
gain was seen between boys and girls and be- 
tween patients who were treated with high vs. 
normal-risk protocols. o 1996 ~ i i e y - ~ i s s ,  Inc 
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INTRODUCTION 
During the last decade many studies have been pub- 
lished on linear growth of children treated for acute 
lymphoblastic leukemia (ALL), concluding that retarda- 
tion of linear growth during treatment is a common obser- 
vation [l-71. Data about weight gain in these patients 
are limited. Malnutrition leading to loss of weight, as a 
consequence of the disease itself or the side effects of 
chemotherapy, might be one of the causal factors of early 
growth deceleration. Our clinical impression, however, 
is that several patients showed excessive weight gain 
during and after treatment. Other authors also noticed 
obesity in a number of children during and after treatment 
for ALL [8-131, but it  is not clear if all the treatment 
modalities are associated with a higher risk for devel- 
oping obesity. 
In this study we evaluated weight development during 
and after treatment for ALL in order to answer the follow- 
ing questions: 
1. Does the Z-score of weight for height decline during 
the period of treatment of children treated for ALL? 
2. Is the pattern of body weight development influenced 
by treatment? 
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3. Could we identify treatment factors related to the pat- 
tern of weight development in these patients? 
PATIENTS AND METHODS 
Patients 
Ninety-two consecutive patients with ALL treated at 
the Department of Paediatric Oncology of the University 
Hospital Nijmegen between 1972 and 1988 were included 
in the study. Data about age and sex are shown in Table 
I. Since central nervous system (CNS) involvement could 
cause hypothalamic dysfunction [ 141, patients with CNS 
involvement were excluded from the study. All patients 
had entered into first remission within 6 weeks after 
diagnosis. Patients with relapse of their disease were ex- 
cluded from the study. 
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TABLE I. Mean Aces at Diagnosis. the Range of the Apes. and the Sexes of the Patients in Different Treatment Groups 
Protocol 6 High-risk Normal-risk 
(n = 15) (n = 77) Dexa (n = 19) Pred (n = 11) CI (n = 54) Non-CI (n = 38) 
8 6 35 11 7 21 20 
P 9 42 8 4 33 18 
Mean age (years) 6.1 5.2 5.5 5.5 5.5 5.5 
Ranee 1.1-15.9 0.6-15.5 2.3-12.3 1.6- 13.9 0.6-15.9 1.1-14.4 
Treatment 
Depending on the risk factor of leukemia, patients were 
divided into two groups. Group I included 77 patients with 
normal-risk leukemia, i.e., they had a leukocyte count in 
the peripheral blood <50,000/mm3, without mediastinal 
enlargement. This group was treated according to the 
consecutive protocols 2,3,5,  and 6 of the Dutch Leukemia 
Working Group. Protocols 2,3, and 5 comprised induction 
treatment with vincristine (VCR), prednisone (Pred), with 
or without L-asparaginase (L-As~),  and maintenance treat- 
ment with 6-mercaptopurine (6-MP), methotrexate 
(MTX) alternated with VCR and Pred. 
Thirty patients were treated according to protocol 6, 
19 of whom (group Ia) received induction treatment with 
VCR, dexamethasone (Dexa) 6 mg/m2, and L - A s ~  and 
maintenance treatment with 6-MP, MTX alternated with 
VCR, Dexa. Eleven patients (group Ib) received the same 
treatment with only a difference in the corticosteroid med- 
ication. In these patients Dexa was replaced by Pred 40 
mg/m2, a dose nearly equal on the basis of glucocorti- 
coid activity. 
Group I1 included 15 patients with high-risk leukemia, 
i.e., they had a leukocyte count >50,000/mm3 and/or 
mediastinal enlargement. They were treated according to 
a high-risk protocol comprising induction treatment with 
cyclophosphamide (Cyclo), VCR, Pred, L - A s ~ ,  and 
Adriamycin (Adria). The maintenance treatment con- 
sisted of 6-MP, MTX, and Cyclo alternated with VCR, 
Pred, Adria, and cytosine-arabinoside (Ara-C). 
Depending on the method of CNS prophylaxis, patients 
were divided in two groups. Group A, which included 54 
patients treated between 1972 and 1984, received cranial 
irradiation (CI). Thirty-seven patients received a dose of 
24 Gy in 13 fractions over 17 days and five doses of 
MTX and Pred intrathecally (it.) and 17 patients received 
18 Gy CI in 10 fractions over 14 days and five doses of 
MTX and Pred i.t. (1972-1984). None of the patients 
received spinal irradiation. The timing of the CI was 5-6 
weeks after diagnosis for all patients. Duration of follow- 
up was up to 12 years. 
Group B, which included 38 patients treated between 
1984 and 1988, did not receive CI. The CNS prophylaxis 
in these patients consisted of high-dose MTX intrave- 
nously combined with MTX and Pred i t .  During mainte- 
nance treatment, eight doses of MTX, Pred, and Ara-C 
were given i.t. Duration of follow-up was up to 4.5 years. 
Forty-three of 77 patients with normal-risk and 11 of 
15 patients with high-risk leukemia received CI. The 
number of patients during the follow-up period is shown 
in Table 11. 
Measurements and Methods 
Patients’ heights and weights were measured by expe- 
rienced staff. During the 2 years of treatment, patients 
were measured 8-12 times per year and during the years 
of follow-up one to four times per year. Weight for height 
was studied. In order to compare the patients’ groups 
with the general population, Z-scores were calculated for 
weight for height using Dutch reference values [ 151. The 
Z-score is defined as the difference between a patients’ 
weight and the stature and sex appropriate mean divided 
by the corresponding standard deviation. Weight for 
height is known to be positively skewed distributed, there- 
fore, a log-transformation after translation In (x-c) was 
applied comparable to the method developed by van ’t 
Hof et al. [16]. The translation (c) is stature and sex 
dependent. The translation was chosen so that a symmet- 
ric distribution with regard to the Plo, Pso, and Pg0 was 
obtained. The transformed distribution was used for the 
calculation of the Z-scores. Estimates of the Z-scores at 
regular time intervals were obtained by interpolation in 
the individual Z-score curves. 
Statistical Analysis 
Statistical comparisons were made using Student’s 
t-test and analysis of variance (ANOVA). Significance 
was accepted for P < 0.05. 
RESULTS 
In order to investigate the influence of different gluco- 
corticoids on body weight development, we compared 
the Z-scores of weight for height of patients treated ac- 
cording to protocol 6 of the Dutch Leukemia Working 
Group with Dexa (group Ia) with the Z-scores of patients 
who received Pred instead of Dexa (group Ib) (Fig. 1). The 
chemotherapy in both groups was the same and neither of 
these patients received CI. At diagnosis, the Z-score of 
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TABLE 11. Number of Patients During Follow-Up (n = 92)* 
Duration in follow-up 
(years) 0 0.25 1 2 3 4 4.5 5 6 7 8 9 10 11 12 
CI (group A) 45 54 54 54 54 53 52 51 41 45 42 41 33 26 19 
No irradiation, exclusive 15 19 19 19 14 13 11 
No irradiation 
Dexa patients (group B) 
Protocol 6: Dexa (group Ia) 14 19 19 19 18 13 7 
Protocol 6: Pred (group Ib) 8 1 1  11 I 1  6 6 5 
Other protocol 7 8 8 8 8 7 6  
*A number of the initial values were missing. At 3 months after diagnosis all patients had entered the averages. 
* *  * * *  * * *  '1 
-2 treatment I 
I I I ~ I ~ I , , '  
0 1 2 3 4 
follow-up after diagnosis [years] 
Fig. 1. Mean Z-scores ( ISEM) of weight for height of patients 
treated for ALL according to protocol 6 of the Dutch Leukemia Working 
Group. The patients receiving Dexa (solid line), n = 19, are compared 
with the patients receiving Pred (broken line), n = 11. * P  < 0.05, 
**P < 0,005, indicating the t-test significance level. 
weight for height of group Ia was -0.1 5 1.3 (LSD) and 
of group Ib -0.4 L I. 1. This difference is not significant. 
Three months after start of therapy, the Z-score was 
0.5 5 1 . I  for group Ia and -0.8 L 1.4 for group Ib. The 
difference is significant ( P  = 0.01). In order to investigate 
whether the baseline difference in Z-scores of +0.3 in 
the two groups influenced the significance at 3 months, 
and to examine whether the difference at 3 months could 
be an artifact due to the five and three patients that were 
added to each group, respectively, we calculated the 
change from the baseline: Z (Z = Z, - Zo, Z, is the Z- 
score at 3 months and Zo is the Z-score at diagnosis) of 
the 14 and 8 patients at 3 months. The Z of the 14 patients 
treated with Dexa was 0.5 2 0.8 and of the 8 patients 
treated with Pred was -0.2 2 0.8. This difference is also 
significant ( P  = 0.04). A significant difference between 
the two groups persisted during the whole follow-up pe- 
riod of 4.5 years. 
As treatment with Dexa has a clear influence on weight 
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Fig. 2. Mean Z-score ( 5 E M )  of weight for height of patients treated 
for ALL with prophylactic CI (solid line), n = 54, or withoutprophylac- 
tic CI (broken line), n = 19. All patients received Pred as corticosteroid. 
* P  < 0.05, **P < 0.01, indicating the ANOVA significance level. 
for height, 19 patients treated with Dexa, all from protocol 
6, were excluded from further analysis. 
By means of two-way ANOVA, the influence of sex 
and CI on weight for height was studied. The Z-scores 
of weight for height of the irradiated group compared 
with the Z-scores of patients who did not receive CI are 
shown in Figure 2. No significant differences between 
the groups were shown during the first year of therapy. 
At 2 and 4 years from diagnosis, the Z-scores were, 
respectively, -0.2 2 1.1 and 0.0 f 1.2 for the non-CI 
group and 0.4 -t 1.1 and 0.7 t 0.9 for the patients who 
received CI. These differences are significant, P values, 
respectively, 0.04 and 0.05. 
Figure 3 shows the Z-scores of weight for height of 
the irradiated patients during the follow-up period of 12 
years. At the end of treatment, 2 years after diagnosis, 
the Z-score was 0.4 ? 1.1. Two years after cessation of 
therapy, the Z-scores were more positive: 0.7 ? 0.9. 
The Z-score remained above the mean of the normal 
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patients who received Pred instead of Dexa showed nor- 
mal weight development during the second year of ther- 
apy and after finishing treatment. Another study [ 131 has 
also identified CI as a risk factor for developing obesity. 
CI is also associated with impaired height growth [ 13,181. 
Some authors [ 13,181 suggested that compromised height 
is a major contributor of obesity and occurs when height 
compromise is not accompanied by parallel weight com- 
promise. However, in the study of Schell et al. [18], 
patients receiving craniospinal irradiation were shown to 
be at increased risk for abnormally short stature but not 
for obesity. This finding suggests that other factors than 
just compromised height are responsible for obesity. 
It is well known that especially endocrine disorders 
causing blunted growth are attended with overweight such 
as hypothyroidism, hypercortisolism, and growth hor- 
mone deficiency. Hypothalamic-pituitary dysfunction in- 
volving corticotropin and thyroid-stimulating hormone 
has not been demonstrated in children treated for ALL 
[20,21]. The impaired linear growth seen in children after 
CI has been thought to be attributed to minor abnormali- 
ties in the secretion of growth hormone [22,23]. Dacou- 
Voutetakis et al. [22] showed transient alterations in 
growth hormone secretion early after CI in children 
treated for ALL. A quantitative reduction in growth hor- 
mone secretion during puberty of children treated for 
ALL has been shown by Crowne et al. [23], suggesting 
that CI causes damage to the hypothalamic-pituitary axis 
affecting the secretion of growth hormone. The hypothal- 
amus seems more vulnerable to radiation damage than 
the anterior pituitary [24]. Hypothalamic damage per se 
may cause obesity, however, the reported cases of hypo- 
thalamic obesity in children with ALL have always been 
demonstrated in patients with leukemic infiltration of the 
brain [14]. Studies on growth hormone profiles of children 
after low-dose CI [23] or total body irradiation [25] show 
a disturbance of frequency modulation of growth hormone 
secretion. Both studies [23,25] postulate that disturbance 
of somatostatin secretion is the underlying mechanism 
for this observation. Our hypothesis is that neurosecretory 
dysfunction is responsible for the excessive weight gain 
in patients who received CI. 
Excess of weight gain during and after treatment for 
ALL is also shown in children treated with Dexa, whereas 
children treated with Pred in an equivalent dose showed 
normal weight development. Besides the well-known pe- 
ripheral effects of corticosteroids on growth and weight 
[26], glucocorticoids also exert an effect on the regula- 
tion of growth hormone secretion [27]. High-dose Pred 
(40 mg/m*/day) used in the treatment for ALL resulted 
in decreased growth hormone secretion during deep sleep 
as well as in response to arginine, insulin, and growth 
hormone releasing hormone administration [28]. Dexa, 
in a dose of 10 mg/mz/day, completely suppressed the 
spontaneous growth hormone secretion in patients treated 
1 4  
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Fig. 3. 
patients with follow-up of 12 years. 
Mean Z-scores (+SEM) of weight for height of the irradiated 
population during the whole period of follow-up. The 
Z-score 12 years after diagnosis was 0.4 ? 1.0. 
No differences in body weight development were no- 
ticed between boys and girls and between patients treated 
according to a normal-risk protocol vs. patients treated 
according to a more intensive high-risk protocol. 
DISCUSSION 
At diagnosis, the weight for height of patients in this 
study was not significantly different from the weight for 
height of the normal population. All patient groups, with 
the exception of the group of patients treated with Dexa, 
showed loss of weight during the first 3 months of treat- 
ment. The underweight of these patients during this phase 
of therapy could have attributed to the impairment of 
height growth, which was also demonstrated in our pa- 
tients [ 171. During the next 3-6 months, weight for height 
of the patients increased to normal, however, weight for 
height of the irradiated patients further increased during 
the second year of treatment and the first year after cessa- 
tion of therapy. After this period, the weight for height 
of these patients stabilized but the Z-score remained 
above the mean of the normal population during the whole 
All studies [8-13,181 but one [19], with respect to 
weight, reported an increased weight velocity during or 
after treatment for ALL. Different factors as lack of physi- 
cal exercise and poor dietary habits [9,13] have been 
suggested to contribute to the excess weight gain in these 
patients who have suffered a serious illness. In this study, 
however, there is clear evidence that two treatment modal- 
ities, i.e., CI and treatment with Dexa, are associated with 
excessive weight gain. Patients treated without CI and 
follow-up. 
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for ALL 1291. The inhibiting action of corticosteroids on 
growth hormone responses seems to be mediated by an 
enhancement of the somatostatin effect at the pituitary 
level (271. 
Increase of weight in patients treated with Dexa is 
immediately shown after start of treatment, while all other 
patients show loss of weight during this phase of intensive 
chemotherapy. The loss of weight of most patients during 
the first months of therapy is presumably due to the side 
effects of cytotoxic drugs such as nausea and vomiting 
resulting in inadequate nutrition. Dexa, and not Pred, 
appears to circumvent this action and leads immediately 
after the start of treatment to excessive weight gain. It 
could be speculated that excessive weight gain after treat- 
ment with Dexa is also a consequence of neurosecretory 
dysfunction and that Dexa exerts a stronger central effect 
than Pred. 
In patients who had undergone CI, the overweight 
persisted during the whole follow-up period of 12 years. 
In view of the age distribution of the patients included 
in the study, we may conclude that, compared to age and 
height matched controls, the overweight of these patients 
persisted during puberty and adolescence. It is not yet 
clear if overweight in the Dexa-treated patients also per- 
sists during such a long period of time. 
Dexa has proven in in vitro studies to have a stronger 
antileukemic effect than Pred [30]. So, in the future, Dexa 
could become a more common drug in the treatment of 
ALL. As obesity has serious long-term psychological 
and medical consequences, awareness of this potential 
complication could contribute to its prevention. 
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